EDUARDO
DÍAZ-RUBIO GARCÍA
Investigador hasta 2020
JAVIER
SASTRE VALERA
Profesor asociado de Ciencias de la Salud
Publicaciones en las que colabora con JAVIER SASTRE VALERA (85)
2023
2022
-
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer
Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210
-
Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets
Cancers, Vol. 14, Núm. 21
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
2020
-
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected
Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116
2019
2018
2016
-
C8-T1 radiculopathy due to an intradural extramedullary metastasis of a pancreatic neuroendocrine tumor: Case report and review of the literature
Pancreas, Vol. 45, Núm. 5, pp. 772-779
-
Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable CT3-4 or N+ rectal cancer: Five-year disease-free survival results of a single-center series
Clinical Colorectal Cancer, Vol. 15, Núm. 2, pp. 128-134
2015
-
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours
European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380
-
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02
Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324
-
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy
Molecular Diagnosis and Therapy, Vol. 19, Núm. 6, pp. 397-408
-
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer
Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541
2014
-
Impact of cetuximab in current treatment of metastatic colorectal cancer
Expert Opinion on Biological Therapy, Vol. 14, Núm. 3, pp. 387-399
-
Role of cetuximab in first-line treatment of metastatic colorectal cancer
World Journal of Gastroenterology, Vol. 20, Núm. 15, pp. 4208-4219
-
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
World Journal of Gastroenterology, Vol. 20, Núm. 20, pp. 6092-6101
2013
-
Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer
Oncologist, Vol. 18, Núm. 8, pp. 917-923
-
Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: Efficacy and safety data according to liver function
Clinical and Translational Oncology, Vol. 15, Núm. 2, pp. 146-153
-
Targeted therapies in older patients with metastatic colorectal cancer
Management of Colorectal Cancers in Older People (Springer-Verlag London Ltd), pp. 141-159